Cargando…
Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from −0.78% to −1.64% over 52–104 weeks, and i...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951211/ https://www.ncbi.nlm.nih.gov/pubmed/29780260 http://dx.doi.org/10.2147/DMSO.S134960 |